Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.
Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451) / E. Tremoli, G. Morazzoni, P. Maderna, S. Colli, R. Paoletti. - In: THROMBOSIS RESEARCH. - ISSN 0049-3848. - 23:6(1981 Sep 15), pp. 549-553. [10.1016/0049-3848(81)90178-X]
Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451)
E. TremoliPrimo
;S. ColliPenultimo
;R. PaolettiUltimo
1981
Abstract
Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
